UCB-HPDSC / BMS - LARVOL DELTA

Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT) with Human Placenta-Derived Stem Cells (HPDSC) Combined with Unrelated Cord Blood (UCB) for Malignant and Non-Malignant Disorders (IND 14949) (TCT-ASTCT-CIBMTR 2020) - "GVHD prophylaxis consisted of tacrolimus and MMF as previously described (Bhatia/Cairo, BBMT 2009). These results suggest that UCB plus HPDSCs for Allo-HSCT is safe and well tolerated. Median day to platelet engraftment was lower than previously reported using UCB alone (Geyer/Cairo.BJH 2011). Probability of Grade 2-4 aGVHD was lower than previously reported using UCB alone, possibly due to the immunomodulatory effect of HPDSCs (Geyer/Cairo.BJH 2011)."

CD34 • CD8 • NCAM1

Hematopoietic Stem Cell Transplantation with Human Placenta-Derived Stem Cells Combined with Unrelated Cord Blood for Malignant and Non-Malignant Disorders (IND 14949) (TCT-ASBMT-CIBMTR 2019) - "GVHD prophylaxis consisted of tacrolimus and mycophenolate mofetil as previously described (Bhatia/Cairo, BBMT 2009). To date, 28 patients 18 years were enrolled, 15 males and 13 females. Mean age in years SD was 6.85.5. There were 12 patients with non-malignant disease including ALD (2), CAT (1), CGD (1), SCID (2), dyskeratosis congenita (1), congenital neutropenia (1), SAA (2), LCH (1), and SDS (1) and 16 patients with malignant disease including pre B-cell ALL- CR1 (4), pre B-cell ALL - CR2 (4), T-cell ALL CR1 (1), AML-CR1 (4), JMML-CR1 (1), TLL - CR1 (1), and BL - CR2 (1)."